Bristol Myers Squibb is already aiming to launch more than 10 new medicines by 2030. | SAN FRANCISCO—Bristol Myers Squibb is ...

In just three months, Phlow and Enveda generated and analyzed nearly 20,000 unique reactions, creating one of the largest high-quality datasets of its kind. The resulting uniform dataset is ...

Teva has penned a second pact with Royalty Pharma, this time securing up to $500 million to support the clinical development ...

AI and machine learning are revolutionizing drug discovery, development, and lifecycle management, addressing industry ...

Enter generative AI, which the pharma industry is adopting at a terrific rate. By ingesting and analysing vast biological ...

Industry-Leading Platform Achieves 94% Accuracy with Real-Time Machine Learning, Providing Open-Access to Critical CNS Drug Development Technology Additional Predictive, Analytic and Descriptive ...

This agreement with Royalty Pharma enables us to advance our science more efficiently and accelerate our pipeline to deliver meaningful solutions for patients worldwide,” said Richard Francis, Teva’s ...

Silo Pharma, Inc., a biopharmaceutical company focused on developing innovative treatments for mental health and chronic pain, announced in a recent letter to shareholders that it expects to submit an ...

Pharmaceutical companies are getting a fresh look for a range of drugs in development, plus a regulatory reprieve.

Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations Financing ...

U.S. pharmaceutical company Eli Lilly plans to disclose the top-line results of its phase 3 clinical trial for ‘remternutux,’ a new drug candidate being developed as a successor to its Alzheimer’s ...

In our final batch of Changing Faces columns for 2025, we’re detailing a flurry of senior leadership appointments in recent ...